Literature DB >> 31444696

Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy.

Antonio B Porcaro1, Alessandro Tafuri2,3, Marco Sebben2, Tania Processali2, Marco Pirozzi2, Aliasger Shakir3, Nelia Amigoni2, Riccardo Rizzetto2, Matteo Brunelli4, Filippo Migliorini2, Salvatore Siracusano2, Walter Artibani2.   

Abstract

OBJECTIVES: The aim of this study is to evaluate the association between total testosterone density (TTD), defined as the ratio of serum TT to prostate volume (PV), and high tumor load (HTL) in low-risk prostate cancer (PCA) patients who underwent radical prostatectomy.
MATERIALS AND METHODS: Tumor load was defined as the percentage of prostate volume invaded by cancer (PPI-PCA) in the surgical specimen. Pathologic features including tumor upgrading, upstaging or positive surgical margins in the specimen defined unfavorable disease (UD). PSA, TT, PSA density (PSAD), TTD, percentage of biopsy positive cores (BPC), PV and body mass index (BMI). The association of factors with the risk UD and HTL was evaluated by statistical methods.
RESULTS: The cohort included 144 consecutive low-risk PCA patients. Overall, 104 patients (72.2%) had at least one feature indicating UD. TTD was associated with BMI, TT, PSA, PV and PPI-PCA ≥ 20% defined as HTL. A higher PPI-PCA was associated with an increased risk of UD with a fair discriminant power (area under the curve, AUC = 0.775; p < 0.0001). Patients with PPI-PCA > 20% were considered the study group versus patients with a PPI-PCA < 20% (control group). BPC, PSAD and TTD were independently associated with the risk of HTL (PPI-PCA ≥ 20%) with receiver-operating characteristics (ROC) curves indicating the same discriminant power for BPC (AUC = 0.628; p = 0.013), PSAD (AUC = 0.611; p = 0.032) and TTD (AUC = 0.610; p = 0.032).
CONCLUSIONS: Among low-risk PCA patients, TTD is associated with the risk of HTL, which is an independent predictor of UD and should be evaluated in the management of these patients.

Entities:  

Keywords:  Low-risk prostate cancer; Prostate cancer; Prostate volume; Testosterone density; Total testosterone

Mesh:

Substances:

Year:  2019        PMID: 31444696     DOI: 10.1007/s11255-019-02263-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  43 in total

1.  Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women.

Authors:  Fernand Labrie; Alain Bélanger; Patrick Bélanger; René Bérubé; Céline Martel; Leonello Cusan; José Gomez; Bernard Candas; Isabelle Castiel; Véronique Chaussade; Claire Deloche; Jacques Leclaire
Journal:  J Steroid Biochem Mol Biol       Date:  2006-04-18       Impact factor: 4.292

2.  Protocol for the examination of specimens from patients with carcinoma of the prostate gland.

Authors:  John R Srigley; Peter A Humphrey; Mahul B Amin; Sam S Chang; Lars Egevad; Jonathan I Epstein; David J Grignon; James M McKiernan; Rodolfo Montironi; Andrew A Renshaw; Victor E Reuter; Thomas M Wheeler
Journal:  Arch Pathol Lab Med       Date:  2009-10       Impact factor: 5.534

3.  Clinical factors stratifying the risk of tumor upgrading to high-grade disease in low-risk prostate cancer.

Authors:  Antonio B Porcaro; Salvatore Siracusano; Nicolò de Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Tania Processali; Mattia Cerasuolo; Daniele Mattevi; Davide Inverardi; Maria A Cerruto; Matteo Brunelli; Walter Artibani
Journal:  Tumori       Date:  2018-05-08       Impact factor: 2.098

Review 4.  Diabetes and the risk of biochemical recurrence in patients with treated localized prostate cancer: a meta-analysis.

Authors:  Qingling Hua; Yanzhe Zhu; Hu Liu; Xiaobing Ye
Journal:  Int Urol Nephrol       Date:  2016-05-11       Impact factor: 2.370

5.  Comparison of prostate size in university and Veterans Affairs Health Care System patients with negative prostate biopsies.

Authors:  M K Terris; A F Prestigiacomo; T A Stamey
Journal:  Urology       Date:  1998-03       Impact factor: 2.649

6.  Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study.

Authors:  Frederick C W Wu; Abdelouahid Tajar; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe Casanueva; Gianni Forti; Aleksander Giwercman; Ilpo T Huhtaniemi; Krzysztof Kula; Margus Punab; Steven Boonen; Dirk Vanderschueren
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

7.  A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; J E Tomaszewski; A Wein
Journal:  Urology       Date:  1998-10       Impact factor: 2.649

8.  Anatomic radical prostatectomy: evolution of the surgical technique.

Authors:  P C Walsh
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

9.  Prostate-specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low-risk prostate cancer.

Authors:  Antonio B Porcaro; Davide Inverardi; Paolo Corsi; Marco Sebben; Giovanni Cacciamani; Alessandro Tafuri; Tania Processali; Marco Pirozzi; Daniele Mattevi; Davide De Marchi; Nelia Amigoni; Riccardo Rizzetto; Maria A Cerruto; Matteo Brunelli; Salvatore Siracusano; Walter Artibani
Journal:  Minerva Urol Nefrol       Date:  2018-10-03       Impact factor: 3.720

10.  Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.

Authors:  Matteo Ferro; Giuseppe Lucarelli; Dario Bruzzese; Giuseppe Di Lorenzo; Sisto Perdonà; Riccardo Autorino; Francesco Cantiello; Roberto La Rocca; Gian Maria Busetto; Amelia Cimmino; Carlo Buonerba; Michele Battaglia; Rocco Damiano; Ottavio De Cobelli; Vincenzo Mirone; Daniela Terracciano
Journal:  Oncotarget       Date:  2017-03-14
View more
  4 in total

1.  Preoperative endogenous testosterone density predicts disease progression from localized impalpable prostate cancer presenting with PSA levels elevated up to 10 ng/mL.

Authors:  Antonio Benito Porcaro; Alberto Bianchi; Giovanni Mazzucato; Sebastian Gallina; Emanuele Serafin; Alessandro Tafuri; Clara Cerrato; Andrea Panunzio; Stefano Vidiri; Damiano D'Aietti; Rossella Orlando; Davide Brusa; Matteo Brunelli; Salvatore Siracusano; Maria Angela Cerruto; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2022-10-05       Impact factor: 2.266

2.  Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer.

Authors:  Antonio Benito Porcaro; Sebastian Gallina; Alberto Bianchi; Clara Cerrato; Alessandro Tafuri; Riccardo Rizzetto; Nelia Amigoni; Rossella Orlando; Emanuele Serafin; Alessandra Gozzo; Filippo Migliorini; Stefano Zecchini Antoniolli; Vincenzo Lacola; Vincenzo De Marco; Matteo Brunelli; Maria Angela Cerruto; Salvatore Siracusano; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2021-10-22       Impact factor: 2.370

3.  Endogenous testosterone density predicts unfavorable disease at final pathology in intermediate risk prostate cancer.

Authors:  Antonio Benito Porcaro; Alessandro Tafuri; Andrea Panunzio; Riccardo Rizzetto; Nelia Amigoni; Clara Cerrato; Aliasger Shakir; Sebastian Gallina; Alberto Bianchi; Francesco Cianflone; Emanuele Serafin; Alessandra Gozzo; Giacomo Di Filippo; Filippo Migliorini; Giovanni Novella; Matteo Brunelli; Maria Angela Cerruto; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2021-09-27       Impact factor: 2.370

4.  Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.

Authors:  Antonio Benito Porcaro; Andrea Panunzio; Alessandro Tafuri; Giovanni Mazzucato; Clara Cerrato; Sebastian Gallina; Alberto Bianchi; Riccardo Rizzetto; Nelia Amigoni; Emanuele Serafin; Francesco Cianflone; Rossella Orlando; Ilaria Gentile; Filippo Migliorini; Stefano Zecchini Antoniolli; Giacomo Di Filippo; Matteo Brunelli; Vincenzo Pagliarulo; Maria Angela Cerruto; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2022-01-19       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.